share_log

Keybanc Initiates Coverage On Standard BioTools With Overweight Rating, Announces Price Target of $4

Benzinga ·  Jul 12, 2023 16:29

Keybanc analyst Paul Knight initiates coverage on Standard BioTools (NASDAQ:LAB) with a Overweight rating and announces Price Target of $4.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment